A Single-Arm Phase 2a Study of Pexa-Vec (JX-594) Administered by Weekly Intravenous (IV) Infusions in Patients with Metastatic, Refractory Renal Cell Carcinoma (RCC)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Oct 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Sep 2019 Results tracking oncolytic virus-specific CD8+ T cells with epitope-based, HLA-agnostic peptides in a renal cell carcinoma, presented at the 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium
10 Feb 2018 Status changed from recruiting to active, no longer recruiting according to results presented at the 2018 Genitourinary Cancers Symposium.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com